Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-062070
Filing Date
2023-11-09
Accepted
2023-11-09 16:15:29
Documents
85
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q dnth-20230930.htm   iXBRL 10-Q 2632438
2 EX-10.12 dnth-ex10_12.htm EX-10.12 75706
3 EX-31.1 dnth-ex31_1.htm EX-31.1 19848
4 EX-31.2 dnth-ex31_2.htm EX-31.2 19966
5 EX-32 dnth-ex32.htm EX-32 19076
  Complete submission text file 0000950170-23-062070.txt   10757902

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT dnth-20230930_def.xml EX-101.DEF 367523
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnth-20230930_pre.xml EX-101.PRE 482849
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT dnth-20230930_cal.xml EX-101.CAL 52373
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnth-20230930_lab.xml EX-101.LAB 566155
10 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnth-20230930.xsd EX-101.SCH 75087
79 EXTRACTED XBRL INSTANCE DOCUMENT dnth-20230930_htm.xml XML 1971022
Mailing Address 300 TECHNOLOGY SQUARE 8TH FLOOR CAMBRIDGE MA 02139
Business Address 300 TECHNOLOGY SQUARE 8TH FLOOR CAMBRIDGE MA 02139 857-201-2700
Dianthus Therapeutics, Inc. /DE/ (Filer) CIK: 0001690585 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38541 | Film No.: 231392635
SIC: 2834 Pharmaceutical Preparations